Case report reveals cognitive decline due to nivolumab-induced encephalitis in gastric cancer, suggesting early recognition is crucial.
This case highlights an exceptionally rare instance of nivolumab-induced limbic encephalitis in a patient with GC. While our patient recovered spontaneously after drug discontinuation without corticosteroids, the key clinical implication is that new-onset cognitive decline in elderly patients receiving ICIs should not be misattributed to dementia progression. Early recognition of neurological immune-related adverse events is essential, as continued ICI therapy in unrecognized cases may result in irreversible or even fatal outcomes.
No takes yet. Share an insight, caveat, or question.
SUMIYOSHI et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: